Psychedelic policy is moving faster than most people realize - and the next 12 months could decide which therapies reach patients first.

On the Season 6 premiere of Psychedelic Brain Science, Dr. Alaina Jaster is joined by Josh Hardman, Founder of Psychedelic Alpha.

Together they break down the regulatory sprint, the companies closest to the finish line, and why "approval" may not mean access as quickly as you think.

They also get into the broader policy picture: where decriminalization appears to be slowing, how medicalized models are taking hold why the psychedelics conversation is increasingly about more than one pathway, including the growing role of non-hallucinogenic neuroplastogens.


To learn more and explore the various trackers at Psychedelic Alpha visit: https://psychedelicalpha.com/

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Psychedelic Brain Science. Innehållet i podden är skapat av Psychedelic Brain Science och inte av, eller tillsammans med, Poddtoppen.